Hypertrophic cardiomyopathy secondary prevention

Jump to: navigation, search

Hypertrophic Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypertrophic Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertrophic cardiomyopathy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertrophic cardiomyopathy secondary prevention

CDC on Hypertrophic cardiomyopathy secondary prevention

Hypertrophic cardiomyopathy secondary prevention in the news

Blogs on Hypertrophic cardiomyopathy secondary prevention

Directions to Hospitals Treating Hypertrophic cardiomyopathy

Risk calculators and risk factors for Hypertrophic cardiomyopathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening. Once HCM has been identified in a family, immediate testing of all family members will help to identify those at risk. Both imaging and genetic testing might be helpful. Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.

Secondary Prevention

Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening by means of:[1][2][3][4][5][6][7].


  • Echocardiography
  • MRI
  • Genetic testing

Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.

ICD

Indications for implantable cardioverter-defibrillator (Secondary prevention)

  • Survivors of cardiac arrest
  • Sustained spontaneous ventricular arrhythmia

References

  1. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.
  2. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.
  3. Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.
  4. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.
  5. Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.
  6. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE (2005). "Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome". J. Am. Coll. Cardiol. 45 (8): 1340–5. doi:10.1016/j.jacc.2005.02.011. PMID 15837284. Unknown parameter |month= ignored (help)
  7. Pelliccia A, Fagard R, Bjørnstad HH; et al. (2005). "Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology". Eur. Heart J. 26 (14): 1422–45. doi:10.1093/eurheartj/ehi325. PMID 15923204. Unknown parameter |month= ignored (help)

Linked-in.jpg